Compugen Ltd.
CGEN.TA
Get informed when a big investor buys or sells
+ FollowMarket Cap$218.42M
Close$
Share Statistics
| Market cap | $218.42 Million |
|---|---|
| Enterprise Value | $222.62 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 39.66% |
|---|---|
| Return on Assets | 25.43% |
| Return on Invested Capital | 29.76% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.01 |
| Enterprise Value to EBIT | 6.46 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Compugen Ltd
75 employees
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...